Hi Joe
Nothing has changed
We are in the Non Ambulant space with DMD and Limb girdle R2
Sarepta has limb girdle but not R2 science
If we only have DMD in Europe it’s still a $5 stock
Sarepta can’t market their Dmd drugs in Europe
FDA has set a prcedent. ( no need to show efficacy and safety data )
So we just have to replicate the end points pUL -2
and we should be able to market our drugs in Europe and USA..
Sarepta FDA Hearing, page-37
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.003(4.17%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.5¢ | 7.7¢ | 7.4¢ | $41.9K | 556.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26764 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 96655 | 1 |
View Market Depth
| Last trade - 15.44pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.003 ( 4.11 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.7¢ | 7.4¢ | 167731 | ||
| Last updated 15.44pm 29/05/2024 ? | |||||
| PER (ASX) Chart |